These data indicated that CYP2J2/EETs was a potential target for lung hyperpermeability induced by LPS treatment, which may contribute to the development of new therapeutic approaches for pulmonary edema and other diseases caused by abnormal vascular permeability. The gene discussed is CYP2J2; the disease is pulmonary edema.